United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Reduces Stake in Thermo Fisher Scientific Inc. $TMO

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,165 shares of the medical research company’s stock after selling 3,045 shares during the period. Thermo Fisher Scientific accounts for approximately 1.7% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s portfolio, making the stock its 20th largest holding. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Thermo Fisher Scientific were worth $43,857,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.5% during the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,428 shares of the medical research company’s stock worth $579,000 after acquiring an additional 62 shares during the period. Harfst & Associates Inc. boosted its position in shares of Thermo Fisher Scientific by 183.7% during the 2nd quarter. Harfst & Associates Inc. now owns 3,430 shares of the medical research company’s stock valued at $1,391,000 after acquiring an additional 2,221 shares during the last quarter. GM Advisory Group LLC increased its position in shares of Thermo Fisher Scientific by 32.5% in the second quarter. GM Advisory Group LLC now owns 2,872 shares of the medical research company’s stock worth $1,165,000 after purchasing an additional 704 shares during the last quarter. Quadrant Capital Group LLC raised its stake in Thermo Fisher Scientific by 24.2% in the second quarter. Quadrant Capital Group LLC now owns 10,908 shares of the medical research company’s stock valued at $4,423,000 after purchasing an additional 2,126 shares in the last quarter. Finally, OPTIMAS CAPITAL Ltd purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $3,000,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TMO shares. Wells Fargo & Company lifted their price objective on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Stock Down 0.7%

Shares of Thermo Fisher Scientific stock opened at $593.41 on Thursday. The company’s 50 day moving average price is $544.05 and its 200-day moving average price is $477.35. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market capitalization of $222.95 billion, a price-to-earnings ratio of 34.28, a P/E/G ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president owned 21,152 shares in the company, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 52,570 shares of company stock valued at $30,382,352 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.